Background/Aim: Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis often associated with an underlying disease, and clinical data or larger studies are rare. Methods: In this retrospective study, disease characteristics, clinical manifestations, and treatment response were evaluated in a Swiss cohort of PG patients. Results: In participating centers, 34 cases (21 females) of PG were analyzed based on clinical and histological presentation between 2002 and 2012. The mean age at diagnosis was 61.2 years; 50% of the patients experienced only 1 episode of PG. In 13 cases (out of 20), recurrences occurred during PG therapy; 64.1% showed only 1 lesion simultaneously. The predominant localization was the lower limb (67%). The lesions were disseminated in 26.6%. At the time of diagnosis or recurrence, the mean diameter was 37.6 mm and the mean ulcer size was 10.3 cm2. C-reactive protein (CRP) was elevated in 73.2%; leukocytosis was present in 58.9% and neutrophilia in 50.9%. At least 1 associated comorbidity was present in 85% (the most prominent being cardiovascular disease). The most often used systemic treatments were steroids (68.3%), cyclosporine A (31.7%), dapsone (31.7%), and infliximab (13.3%), and the most often used topicals were tacrolimus 0.1% (48.3%) and corticosteroids (35%). PG healed completely at discharge in 50.8%. The average time to diagnosis was 8 months, and the mean duration to healing was 7.1 months. Conclusion: PG is a difficult-to-diagnose skin disease. Here, markers for inflammation such as CRP, leukocytosis, and neutrophilia were elevated in 50-73% of the PG patients.

1.
Meier B, Maul JT, French LE: Pyoderma gangrenosum and Sweet's syndrome: cutaneous manifestations of autoinflammatory disorders (in German). Hautarzt 2016;67:934-939.
2.
Callen JP, Jackson JM: Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007;33:787-802, vi.
3.
Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, White WL, Callen JP: Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000;79:37-46.
4.
Bhat RM: Pyoderma gangrenosum: an update. Indian Dermatol Online J 2012;3:7-13.
5.
Powell FC, Su WP, Perry HO: Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996;34:395-409; quiz 410-412.
6.
Rodriguez-Cerdeira C, Sanchez-Blanco E, Molares-Vila A: Clinical application of development of nonantibiotic macrolides that correct inflammation-driven immune dysfunction in inflammatory skin diseases. Mediators Inflamm 2012;2012:563709.
7.
Marzano AV, Damiani G, Ceccherini I, Berti E, Gattorno M, Cugno M: Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol 2017;176:1588-1598.
8.
Marzano AV, Fanoni D, Antiga E, Quaglino P, Caproni M, Crosti C, Meroni PL, Cugno M: Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. Clin Exp Immunol 2014;178:48-56.
9.
Wollina U: Pyoderma gangrenosum - a review. Orphanet J Rare Dis 2007;2:19.
10.
Baldea A, Gamelli RL: Postoperative pyoderma gangrenosum after elective abdominoplasty: a case report and review of the literature. J Burn Care Res 2010;31:959-963.
11.
Costa J, Monteiro D, Valença-Filipe R, Reis J, Silva A: Pyoderma gangrenosum after breast reduction: a rare complication. J Plast Reconstr Aesthet Surg 2013;66:e336-e337.
12.
McAleer MA, Powell FC, Devaney D, O'Donnell BF: Infantile pyoderma gangrenosum. J Am Acad Dermatol 2008;58:S23-S28.
13.
Callen JP: Pyoderma gangrenosum. Lancet 1998;351:581-585.
14.
Wollina U, Tchernev G: Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr 2014;164:263-273.
15.
Brooklyn T, Dunnill G, Probert C: Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006;333:181-184.
16.
Su WP, Davis MD, Weenig RH, Powell FC, Perry HO: Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004;43:790-800.
17.
von den Driesch P: Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997;137:1000-1005.
18.
Gameiro A, Pereira N, Cardoso JC, Goncalo M: Pyoderma gangrenosum: challenges and solutions. Clin Cosmet Investig Dermatol 2015;8:285-293.
19.
Adişen E, Erduran F, Gürer MA: Pyoderma gangrenosum: a report of 27 patients. Int J Low Extrem Wounds 2016;15:148-154.
20.
Hoetzenecker W, Guenova E, Mitev V, Schanz S, Ulmer A, Fierlbeck G: Treatment of pyoderma gangrenosum with topical factor XIII. Eur J Dermatol 2013;23:653-657.
21.
Greb JE, Gottlieb AB, Goldminz AM: High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. Dermatol Ther 2016;29:482-483.
22.
Agarwal A, Andrews JM: Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther 2013;38:563-572.
23.
Hasselmann DO, Bens G, Tilgen W, Reichrath J: Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature (in English, German). J Dtsch Dermatol Ges 2007;5:560-564.
24.
Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I: Treatment of Skin Disease: Comprehensive Therapeutic Strategies, ed 3. Elsevier, 2010.
25.
Kolios AG, Maul JT, Meier B, Kerl K, Traidl-Hoffmann C, Hertl M, Zillikens D, Röcken M, Ring J, Facchiano A, Mondino C, Yawalkar N, Contassot E, Navarini AA, French LE: Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol 2015;173:1216-1223.
26.
Guenova E, Hoetzenecker W: Case 1-2012: a man with persistent ulcers on the hands. N Engl J Med 2012;366:1450; author reply 1450.
27.
Guenova E, Teske A, Fehrenbacher B, Hoerber S, Adamczyk A, Schaller M, Hoetzenecker W, Biedermann T: Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011;147:1203-1205.
28.
Binus AM, Qureshi AA, Li VW, Winterfield LS: Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 2011;165:1244-1250.
29.
Cabalag MS, Wasiak J, Lim SW, Raiola FB: Inpatient management of pyoderma gangrenosum: treatments, outcomes, and clinical implications. Ann Plast Surg 2013;74:354-360.
30.
Saracino A, Kelly R, Liew D, Chong A: Pyoderma gangrenosum requiring inpatient management: a report of 26 cases with follow-up. Australas J Dermatol 2011;52:218-221.
31.
Vidal D, Puig L, Gilaberte M, Alomar A: Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. J Dermatolog Treat 2004;15:146-152.
32.
Langan SM, Groves RW, Card TR, Gulliford MC: Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol 2012;132:2166-2170.
33.
Suárez-Pérez JA, Herrera-Acosta E, López-Navarro N, Vilchez-Márquez F, Prieto JD, Bosch RJ, Herrera E: Pyoderma gangrenosum: a report of 15 cases and review of the literature (in Spanish). Actas Dermosifiliogr 2012;103:120-126.
34.
Vieira WA, Barbosa LR, Martin LM: Hyperbaric oxygen therapy as an adjuvant treatment for pyoderma gangrenosum (in English, Portuguese). An Bras Dermatol 2011;86:1193-1196.
35.
Jockenhöfer F, Herberger K, Schaller J, Hohaus KC, Stoffels-Weindorf M, Ghazal PA, Augustin M, Dissemond J: Tricenter analysis of cofactors and comorbidity in patients with pyoderma gangrenosum. J Dtsch Dermatol Ges 2016;14:1023-1030.
36.
Herberger K: Pyoderma gangrenosum (in German). Hautarzt 2016;67:753-763.
37.
BFS: Schweizerische Eidgenossenschaft Bundesamt für Statistik, Herz- und Kreislauf-Erkrankungen. 2016. https://www.bfs.admin.ch/bfs/de/home/statistiken/gesundheit/gesundheitszustand/krankheiten/herz-kreislauf-erkrankungen.html.
38.
Hafner J, Nobbe S, Partsch H, Läuchli S, Mayer D, Amann-Vesti B, Speich R, Schmid C, Burg G, French LE: Martorell hypertensive ischemic leg ulcer: a model of ischemic subcutaneous arteriolosclerosis. Arch Dermatol 2010;146:961-968.
39.
Chiba T, Isomura I, Suzuki A, Morita A: Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol 2005;32:199-203.
40.
Reichrath J, Bens G, Bonowitz A, Tilgen W: Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005;53:273-283.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.